EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients

Ria Nagpal, Katie Butler, Nicola Thal, Abigail Hobill, Alice Gage, Maryam Javed, Felix Karst, Azhar Ali Khan, Amy Needleman, Graham Shirling, Henry Stephens, Sharon Vivers und 8 weitere

Transplant International · 2025

DOI: 10.3389/ti.2025.14852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von Ria Nagpal und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine and Transplantation, Royal Free Hospital NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Kidney Transplantation, HLA Antigens, Basiliximab, Immunosuppressive Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphocyte depleting induction is recommended for kidney transplant recipients (KTRs) at high immunological risk, which traditionally includes those with detectable anti-human leucocyte antigen antibodies. Data to support this approach in the modern era of histocompatibility testing are limited. We investigated outcomes in KTRs who underwent Basiliximab induction between 2012–2023 in the UK. We stratified outcomes by levels of sensitisation and T cell epitope mismatch (PIRCHE-II) scores. 1348 KTRs were included; 859 (63.7%) were unsensitised, 351 (26.0%) sensitised (calculated reaction frequency [cRF] 1%–84%), and 138 (10.3%) highly sensitised (cRF 85%–100%). Patient survival, allograft survival, and death-censored graft survival (DCGS) were 97%, 94%, and 97% at 1 year, and 88%, 78%, and 84% at 5 years respectively. There were no differences in outcomes between unsensitised and sensitised recipients; graft survival was lower in highly sensitised patients. T cell epitope mismatch scores were higher in those with rejection at 1 year (ln[PIRCHE+1] 3.94 ± 1.01 no rejection vs. 4.25 ± 0.58 rejection, p = 0.02) and epitope mismatch was associated with early rejection in multivariable analyses (Odds Ratio 1.58, 95% CI 1.01–2.62). Hence, non-depleting induction provides good outcomes in unsensitised and sensitised KTRs. T cell epitope mismatches inform rejection risk in the first post-transplant year.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationHLA AntigensBasiliximabImmunosuppressive AgentsHumansMaleFemaleMiddle AgedGraft SurvivalAdultGraft RejectionHistocompatibility TestingTreatment OutcomeRetrospective StudiesAgedEpitopes, T-Lymphocyte

Stichwörter der Autor:innen

BasiliximabEpitopesHLA allosensitizationrejectionsurvival

Substanzen

HLA AntigensBasiliximabImmunosuppressive AgentsEpitopes, T-Lymphocyte

Autor:innen und Institutionen

  • Department of Renal Medicine and Transplantation, Royal Free Hospital NHS Foundation Trust, London, United Kingdom.
  • Anthony Nolan Histocompatibility Laboratories, London, United Kingdom.
  • UCL Centre for Kidney and Bladder Health, Royal Free Hospital, London, United Kingdom.
  • Anthony Nolan Research Institute, London, United Kingdom.
  • UCL Cancer Institute, London, United Kingdom.

Zitieren

APA

Nagpal, R., Butler, K., Thal, N., Hobill, A., Gage, A., Javed, M., Karst, F., Khan, A. A., Needleman, A., Shirling, G., Stephens, H., Vivers, S., Tavarozzi, F., Mayor, N., Frater, S., Salama, A., Harber, M., Jones, G., Fernando, R., & Evans, R. D. R. (2025). Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients. Transplant International. https://doi.org/10.3389/ti.2025.14852

Vancouver

Nagpal R, Butler K, Thal N, Hobill A, Gage A, Javed M, et al. Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients. Transplant International. 2025. doi:10.3389/ti.2025.14852

BibTeX
@article{Nagpal2025,
  author = {Nagpal, Ria and Butler, Katie and Thal, Nicola and Hobill, Abigail and Gage, Alice and Javed, Maryam and Karst, Felix and Khan, Azhar Ali and Needleman, Amy and Shirling, Graham and Stephens, Henry and Vivers, Sharon and Tavarozzi, Franco and Mayor, Neema and Frater, Sandra and Salama, Alan and Harber, Mark and Jones, Gareth and Fernando, Raymond and Evans, Rhys D R},
  title = {Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2025.14852}
}
Kostenlos starten →